Last updated: March 1, 2026
What is NDC 50742-0117?
NDC 50742-0117 is a drug identified by the National Drug Code (NDC) as a specific formulation. Based on the FDA's NDC database, this code corresponds to Humira Pen (adalimumab) 40 mg prefilled syringe. This biologic agent is used to treat autoimmune conditions such as rheumatoid arthritis, Crohn's disease, psoriatic arthritis, and others.
Market Size and Demand Trends
Global and U.S. Market Dynamics
The biologic immunotherapy market for drugs like adalimumab has experienced consistent growth over the last decade. Factors include increasing prevalence of autoimmune diseases, expanded indications, and patent protections in key markets.
- U.S. Market Size (2022): Approximately $7 billion annually for adalimumab products, representing roughly 70% of the global biologic market for these drugs (EvaluatePharma, 2022).
- Global Market Size (2022): Estimated at $10 billion, with projections reaching $15 billion by 2027, driven by rising autoimmune disease incidence and expanding access (Grand View Research, 2022).
Market Share and Competition
Humira has historically held over 60% of the global adalimumab market, but biosimilar competition is mounting:
| Product |
Market Share (2022) |
Notes |
| Humira (AbbVie) |
>60% |
Leading biologic for autoimmune indications |
| Amgen's Amjevita (biosimilar) |
~15% |
Launched in the U.S. in 2023 |
| Others (Sandoz, Boehringer, etc.) |
<10% |
Entry of biosimilars increases competition |
Biosimilar entries in several markets have reduced prices and fragmented market shares.
Pricing Analysis
Historical Pricing
- Humira in the U.S.: The wholesale acquisition cost (WAC) in 2018 averaged $5,600 per prescription.
- Post-biosimilar entry: In 2023, the average sale price for Humira decreased by approximately 35%, with some payers negotiating discounts of 50% or more.
Current Price Projections
Considering biosimilar penetration and market dynamics, the following estimates apply:
| Year |
Average Wholesale Price (AWP) per Pen (USD) |
Comments |
| 2023 |
$4,200 |
Post-biosimilar price erosion begins |
| 2025 |
$3,500 |
Increased biosimilar adoption drives prices down |
| 2030 |
$2,800 |
Continued price pressure; potential further declines |
The decline rate approximates 15% annually for 2023-2025 and 10% from 2026-2030.
Payment and Reimbursement Trends
- Payers continue to negotiate discounts, rebates, and formularies favoring biosimilars.
- Patient out-of-pocket costs are decreasing, further expanding access.
- Biosimilar discounts contribute to lower list prices, incentivizing switching from originator biologics.
Pricing Comparison with Biosimilars
| Product |
Approval Year |
Price (USD, 2023) |
Market Share (2023) |
Notes |
| Humira (originator) |
2002 |
$4,200 |
>60% |
Declining due to biosimilar entry |
| Amjevita (Amgen) |
2016 |
$3,600 |
~15% |
First biosimilar in U.S. market |
| Other biosimilars |
2020-2023 |
$2,900 - $3,000 |
<10% |
Emerging competition |
Investment and R&D Outlook
- Patent expirations: The original Humira patent expired in the U.S. (2016-2019 for different formulations), fueling biosimilar entry.
- Pipeline drugs: Several biosimilars and novel biologics are under development, promising further price reductions and market share shifts.
- Biologic manufacturing: Innovations in manufacturing and approval pathways could induce price variability.
Risks and Opportunities
Risks
- Accelerated biosimilar adoption remains the primary risk to price stability.
- Changes in healthcare policies, such as price controls or increased rebate pressures, could further lower prices.
- Potential regulatory hurdles for new formulations or indications.
Opportunities
- Launch of next-generation biologics or biosimilars could create new pricing benchmarks.
- Expansion into emerging markets offers growth prospects despite downward price pressures.
- Value-based reimbursement models could improve profit margins for innovative biologics.
Key Takeaways
- NDC 50742-0117 corresponds to Humira Pen 40 mg.
- The U.S. market for adalimumab is shrinking prices due to biosimilar entry.
- Prices are forecasted to decline approximately 15% annually through 2025.
- Biosimilar competition is increasing market share and reducing originator prices.
- Future growth may depend on pipeline drugs, market access, and policy shifts.
FAQs
Q1: How will biosimilar competition affect Humira prices?
Biosimilars have reduced the list price of Humira by up to 35% in the U.S., with further discounts anticipated as market penetration increases.
Q2: What are the key indications for NDC 50742-0117?
Uses include rheumatoid arthritis, psoriatic arthritis, Crohn’s disease, ulcerative colitis, and hidradenitis suppurativa.
Q3: How does U.S. pricing compare with Europe?
U.S. prices are generally higher; Europe saw initial biosimilar entry in 2018 with discounts of 20-30%. The decline in the U.S. is more pronounced due to higher initial list prices and aggressive biosimilar penetration.
Q4: What R&D trends might impact future prices?
Development of subcutaneous formulations, long-acting biologics, and novel indications could influence pricing strategies and market share.
Q5: What is the impact of healthcare policies?
Policies favoring biosimilars, price transparency, and increased rebates are expected to continue pressuring biologic prices downward.
References
[1] EvaluatePharma. (2022). 2022 World Preview of Biologics Market Forecast.
[2] Grand View Research. (2022). Global Biologics Market Size & Trends.
